NCT00622063已完成1 期
An Extension Study for Patients Previously Treated With ARQ 501
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)2 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2006年12月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1
- 试验地点
- 2
- 主要终点
- To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501
研究概览
简要总结
To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent
- •Has previous participated in a clinical trial with ARQ 501 and is eligible for continued treatment
排除标准
- •Have not received previous treatment with ARQ 501 under a treatment protocol
- •Uncontrolled intercurrent illness, uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements
结局指标
主要结局
To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501
时间窗: No time frame
次要结局
- To collect additional safety and tolerability information for ARQ 501 treatment(No time frame)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511Gliomas, MalignantGlioblastoma MultiformeAstrocytomaNCT04327011Tocagen Inc.65
已完成
1 期
An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) ProtocolsAdvanced Solid TumorsNCT01178411ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)60
招募中
不适用
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesBreast CancerLung CancerColon CancerLiver CancerProstate CancerNCT00451022National Cancer Institute (NCI)750
终止
2 期
An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311Alzheimer's DiseaseNCT03531710United Neuroscience Ltd.34
已完成
2 期
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its SafetyCancerNCT04125693Bayer1